18.2
Cryptococcal meningitis is typically caused by the fungus Cryptococcus neoformans.
Infection begins when aerosolized desiccated yeast cells or spores are inhaled from environmental sources, such as aged pigeon droppings.
The spores survive in the lung alveoli, where they can remain extracellular or be phagocytosed by alveolar macrophages.
Here, the spores enlarge and germinate into the fungal form, which expresses two major virulence factors: a capsule that promotes immune evasion, and melanin, which protects against oxidative stress.
Melanin also binds to antifungal agents, reducing the pathogen’s susceptibility to drugs.
The fungus multiplies inside macrophages, exits the cells, and spreads through the bloodstream to the central nervous system.
Here, it produces enzymes like metalloproteinases that help cross the blood–brain barrier.
The fungus enters and multiplies in the cerebrospinal fluid.
This results in inflammation of the meninges and obstruction of CSF outflow, leading to an increase in intracranial pressure.
As a result, patients experience persistent headache, fever, and visual disturbances.
Cryptococcal meningitis is a life-threatening opportunistic infection predominantly associated with HIV/AIDS, accounting for over 100,000 deaths annually worldwide. However, it also affects individuals with other forms of immunosuppression, including those undergoing immunosuppressive therapy, organ transplant recipients, patients with innate immunodeficiencies, and individuals with hematological disorders. The infection is caused mainly by Cryptococcus neoformans and Cryptococcus gattii, encapsulated yeasts that show a strong neurotropism, facilitating their invasion of the central nervous system (CNS).
Inhalation of Cryptococcus spores initiates infection, leading to pulmonary colonization and hematogenous dissemination, particularly to the CNS. The pathogen’s polysaccharide capsule inhibits phagocytosis, while enzymes such as urease and metalloproteinases contribute to increased blood-brain barrier permeability. Immunological responses include antibody-dependent cellular cytotoxicity, natural killer cell activity, and T-cell–mediated immunity although these defenses are often insufficient in immunocompromised hosts.
Clinically, cryptococcal meningitis presents as a subacute meningoencephalitis, with symptoms such as headache, altered mental status, photophobia, and cranial neuropathies. HIV-positive patients often show an attenuated inflammatory response, resulting in subtle or atypical presentations. Diagnosis hinges on cerebrospinal fluid (CSF) analysis, including cryptococcal antigen testing, India ink staining, and culture. Elevated CSF opening pressure is a critical prognostic marker, necessitating frequent monitoring.
Treatment strategies involve a three-phase antifungal regimen: induction with amphotericin B combined with flucytosine, consolidation with fluconazole, and maintenance therapy to prevent relapse. Resource-limited settings often modify this approach due to the unavailability of flucytosine. Interprofessional collaboration among infectious disease specialists, neurologists, pharmacists, and radiologists is crucial for optimizing patient outcomes, ensuring prompt diagnosis, managing complications such as elevated intracranial pressure, and providing long-term follow-up to mitigate recurrence and neurological sequelae.
Cryptococcal meningitis is typically caused by the fungus Cryptococcus neoformans.
Infection begins when aerosolized desiccated yeast cells or spores are inhaled from environmental sources, such as aged pigeon droppings.
The spores survive in the lung alveoli, where they can remain extracellular or be phagocytosed by alveolar macrophages.
Here, the spores enlarge and germinate into the fungal form, which expresses two major virulence factors: a capsule that promotes immune evasion, and melanin, which protects against oxidative stress.
Melanin also binds to antifungal agents, reducing the pathogen’s susceptibility to drugs.
The fungus multiplies inside macrophages, exits the cells, and spreads through the bloodstream to the central nervous system.
Here, it produces enzymes like metalloproteinases that help cross the blood–brain barrier.
The fungus enters and multiplies in the cerebrospinal fluid.
This results in inflammation of the meninges and obstruction of CSF outflow, leading to an increase in intracranial pressure.
As a result, patients experience persistent headache, fever, and visual disturbances.
From Chapter 18:
Now Playing
Fungal and Parasitic Infections
31 Views
Fungal and Parasitic Infections
60 Views
Fungal and Parasitic Infections
34 Views
Fungal and Parasitic Infections
44 Views
Fungal and Parasitic Infections
43 Views
Fungal and Parasitic Infections
33 Views
Fungal and Parasitic Infections
36 Views
Fungal and Parasitic Infections
42 Views
Fungal and Parasitic Infections
36 Views